The Fox Chase Cancer Center (FCCC) demonstrates a continued commitment to clinical cancer research through administrative and scientific involvement with the Eastern Cooperative Oncology Group (ECOG). Participation in the ECOG clinical research programs is an integral component of the cancer research performed at FCCC. Active participation in ECOG activities provides an opportunity for our patients to participate in controlled multidisciplinary trials which are designed to provide the best potential new therapies for a variety of different types of cancer. In turn, FCCC performs an important role in defining the merits of these new therapies. ECOG also provides an important opportunity for the Developmental Therapeutics Molecular Medical program at our Center to interact with a larger number of clinical investigators interested in testing new and innovative therapies to improve survival and increase the cure rate for many different cancers. The Cooperative Group Outreach Program (CGOP) provides the opportunity to support our active affiliates, and their critical data management and nurse oncology functions. Through this program we make available to the community the most current therapeutic options and in turn these treatments are tested in the environment in which they will be most widely applied. The primary objectives of this grant are to (1) maintain a level of accrual to ECOG studies;(2) increase the level of multidisciplinary involvement by integrating key modality-oriented individuals into ECOG activity In our affiliate institutions;(3) Increase our contribution to the scientific activities of ECOG, and (4) maintain a high level of scientific and administrative Involvement In ECOG programs. During the next 6 year period, we anticipate growth In our ECOG accrual and In the impact we have on the scientific activities of the Group.

Public Health Relevance

The funding of this grant to Fox Chase Cancer Center (FCCC) provides opportunities for advancement of novel therapeutics to be evaluated in controlled clinical trials. The Eastern Cooperative Oncology Group (ECOG) is the sum of its component cancer center members. The scientific rationale, protocol development and accrual depend on the contribution of the investigators at FCCC. Taken together this will promote the development of new therapies to improve the outcomes for patients with malignancies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Institute of Fox Chase Cancer Center
United States
Zip Code
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2015) Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. JAMA Oncol 1:369-74
Adams, Sylvia; Gray, Robert J; Demaria, Sandra et al. (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-66
Zeidan, Amer M; Lee, Ju-Whei; Prebet, Thomas et al. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol 167:62-8
Chang, Julie E; Li, Hailun; Smith, Mitchell R et al. (2014) Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood 123:1665-73
Zeidan, Amer M; Lee, Ju-Whei; Prebet, Thomas et al. (2014) Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol 166:352-9
Sanford, Stacy D; Zhao, Fengmin; Salsman, John M et al. (2014) Symptom burden among young adults with breast or colorectal cancer. Cancer 120:2255-63

Showing the most recent 10 out of 53 publications